

## **ALLIGATOR BIOSCIENCE TO PARTICIPATE IN UPCOMING SCIENTIFIC AND INDUSTRY CONFERENCES IN JANUARY AND FEBRUARY 2023**

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that senior company representatives will participate in the following conferences during January and February 2023:

- **Redeye Fight Cancer Day 2023, January 19, Stockholm**  
Søren Bregenholt, Chief Executive Officer of Alligator Bioscience, will present the company, its latest developments, and upcoming catalysts to investors.
- **Aktiespararna "Aktiedagen i Lund", January 31, Lund**  
Søren Bregenholt, Chief Executive Officer of Alligator Bioscience, will present the company, its latest developments, and upcoming catalysts to investors.
- **ØU Life Science Investor Conference, February 22, Copenhagen, Denmark**  
Søren Bregenholt, Chief Executive Officer of Alligator Bioscience, will present the company, its latest developments, and upcoming catalysts to investors.
- **European Bispecific & Multispecific Antibody Congress, February 22 - 23, Amsterdam, Netherlands**  
Laura von Schantz, Vice President of Discovery at Alligator Bioscience, will give a presentation entitled "*Reviewing the Landscape of Obligate MoAs for Bi-/Multispecifics to Prioritise and De-Risk Current and Future Efforts*" at 2.30 pm CET on February 22.

Registration for the conference is open [here](#).

*The information was submitted for publication, through the agency of the contact persons set out below, at 8:00 a.m. CET on January 9, 2023.*

**PRESS RELEASE**

09 January 2023 08:00:00 CET



**For further information, please contact:**

---

Søren Bregenholt, CEO

E-mail: [soren.bregenholt@alligatorbioscience.com](mailto:soren.bregenholt@alligatorbioscience.com)

Phone: +46 (0) 46 540 82 00

LifeSci Advisors

Investor Relations

Guillaume van Renterghem

E-mail: [gvanrenterghem@lifesciadvisors.com](mailto:gvanrenterghem@lifesciadvisors.com)

Phone: +41 (0) 76 735 01 31

**About Alligator Bioscience**

---

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc.

Alligator Bioscience's shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden.

For more information, please visit [alligatorbioscience.com](http://alligatorbioscience.com).

**Attachments**

---

**Alligator Bioscience to Participate in Upcoming Scientific and Industry Conferences in January and February 2023**